IVIG and mABs Therapy
The application of Intravenous Immunoglobulin (IVIG) and monoclonal antibodies (mABs) represents a new area in treating Long Covid, Post Vac and Chronic Illnesses. These conditions involve complex immune dysregulation and inflammatory responses.
IVIG is a concentrated preparation of immunoglobulins derived from pooled human plasma.
The current official indications include symptoms present in chronic illness and many post-viral conditions: Myo- and Pericarditis, Small Fiber Neuropathy but also acute/severe conditions like Sepsis.
Monoclonal antibodies, designed to target specific components of the immune response, present another avenue for intervention.
Both IVIG and mABs are being investigated for their potential to restore immune homeostasis.
Here is a current study regarding the use of IVIG in Long Covid/Small Fiber Neuropathy: https://www.neurology.org/doi/10.1212/NXI.0000000000200244
Anecdotal note: mABs are designed strain-specific, IVIGs are not. To our knowledge there have been no reports of Long Covid/Post Vac patients worsening permanently after IVIG treatment, whereas with mABs there is a risk of side effects worsening a patient under certain circumstances.
The only patients our medical team has observed to worsen temporarily after IVIG treatment were patients with symptoms presenting similar to headaches expanding down to the neck area.
Many of the mABs are discontinued or priced at high level, hence IVIG use has become predominant.
*services supplied by Akamantis Health
Apheresis Center, H.E.L.P. Apheresis & Combination Therapy
Featured In
Member of the Cyprus Medical Association
Dr. Irina Pavlik Marangos
Our Partners and Suppliers
Choose Your Language
Take our free Online Microclots Test!
Our diagnostic screening questionnaire is used by thousands all over the world, clinicians and patients. It gives you an clinical diagnosis on how severely you are affected by microclots, microcirculation and blood flow issues and if further investigation is meaningful.